Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA's Breakthrough Program Needs Higher Standard For Comparators, NEJM Says

Apr 12 2018

• By Michael Cipriano

SC1802_Lego Wall_658035112_1200.jpg

Related Content

Breakthrough, Fast-Track Pathways Match Their Hype Of Reduced Development Times - JAMA

Dec 05 2017

JAMA Study Continues Wave Of Accelerated Approval Criticism Amid Expansion Of Pathway

Aug 28 2017

NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate

May 25 2017

Safety Events For Accelerated Approval Drugs Highlighted As Expansion Looms

May 14 2017

Accelerated Approval: US FDA Defends Size Of Premarket Safety Databases, Confirmatory Endpoints

Mar 05 2018

Mortality In Mind: Survival Analysis Drove <em>Esbriet</em>, <em>Ofev</em> Reviews, If Not Labels

Feb 25 2015

Related Companies

Boehringer Ingelheim GmbH

Alexion Pharmaceuticals Inc.

Genentech, Inc.

Acadia Pharmaceuticals Inc.

Vertex Pharmaceuticals Incorporated

Wellstat Therapeutics Corporation

Additional Topics

United States Research & Development FDA Regulation BioPharmaceutical

More from R&D

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window